跳至主要内容
临床试验/EUCTR2016-003185-26-DK
EUCTR2016-003185-26-DK进行中(未招募)1 期

Qualification of 82Rb PET for measurement of tumor perfusion. Uptake in primary prostate cancer vs healthy prostate - RubiPerf

Aarhus University Hospital0 个研究点开始时间: 2016年8月26日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Male

入选标准

  • •Prostate cancer population
  • •15 high risk prostate cancer patients referred to 68Ga-PSMA PET/CT.
  • •Pausation of medicine according to guidelines for clinical 82Rb PET of the heart
  • •Control population
  • •15 male patients referred to 82RB PET/CT of the heart.
  • •Pausation of medicine according to guidelines for clinical 82Rb PET of the heart
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 15
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 15

排除标准

  • •Prostate cancer population
  • •Age < 50 years or > 85 years
  • •Hormone- or radiationtreatment of prostate cancer (PC)
  • •Radikal prostatektomi
  • •Other malignant diseases than PC
  • •Other severe medical condition
  • •Control population
  • •Age < 50 years or > 85 years
  • •Known PC or other diseases of the prostate (BPH, prostatitis, elevated PSA )
  • •Other malignant diseases than PC
  • •Other severe medical condition

研究者

发起方
Aarhus University Hospital

相似试验